FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Washington, | DC | 20549 |
|-----------------|------|-------|
| vvasiiiiiqtoii, | D.C. | 20343 |

| STATEMENT | OF CHANGES | S IN BENEFICIAL | OWNERSHIP |
|------------------|------------|-----------------|-----------|

| | OMB APPROVAL | | | | | | | | |
|---------------------|--------------------------|-----|--|--|--|--|--|--|--|
| OMB Number: 3235-02 | | | | | | | | | |
| | Estimated average burden | | | | | | | | |
| l | hours per response: | 0.5 | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Address of Reporting Person* <u>Drazba Brian G.</u> | | | | | 2. Issuer Name and Ticker or Trading Symbol MEI Pharma, Inc. [MEIP] | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | | | | |
|---|---|--|--------------|-------------------------------|---|---|-----------------|------|--|--|------------------|--|---|------------------------|---|--|---------|--|---------------------------------------|--|
| | I PHARMA | | (Middle) | | | 3. Date of Earliest Transaction (Month/Day/Year) 07/01/2021 | | | | | | | | X | below) | give title nief Finan | icial (| Other (specify below) al Officer | | |
| 11455 EL CAMINO REAL, SUITE 250 (Street) SAN DIEGO CA 92130 | | | | 4. | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | | |
| (City) | (S | tate) | (Zip) | Doriv | l ativ | | | | | | | | | aiellu Ouwad | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/E | | | actio | 2A. Deemed Execution Date, | | | Code (Instr. 8) | | | or 5. Amount of Securities Beneficially Owned Following Reported | | lly ollowing | Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of ndirect Beneficial Ownership Instr. 4) | | | | | |
| | | | | Dorivo | | | | | Code \ | | Amount | (A) or P | | ice | Transaction(s) (Instr. 3 and 4) | | | | | |
| | | | (| | | | ls, warr | ants | s, options | , с | onverti | ble secu | urities | s) | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | Execution Da | ′ Co | ansaction ode (Instr. | | Derivative E | | 6. Date Exercisab Expiration Date (Month/Day/Year) | | of Securities | | ies g Securi | Derivative Security | | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | Co | ode | v | (A) | (D) | Date Exercisable | | xpiration ate | Title | Amou or Numb of Sha | er | | (Instr. 4) | ni(s) | | | |
| Stock Option (Right to Buy) | \$2.95 | 07/01/2021 | | | A | | 200,000 | | (1) | 0, | 7/01/2031 | Common Stock | 200, | 000 | \$0.00 | 200,000 | 0 | D | | |
| Stock Option (Right to Buy) | \$1.59 | | | | | | | | (2) | 04 | 4/03/2027 | Common Stock | 150, | 000 | | 150,000 | 0 | D | | |
| Stock Option (Right to Buy) | \$2.83 | | | | | | | | (3) | 0' | 7/06/2027 | Common Stock | 50,0 | 000 | | 50,000 | | D | | |
| Stock Option (Right to Buy) | \$4.33 | | | | | | | | (4) | 0 | 6/22/2028 | Common Stock | 130, | 000 | | 130,000 | 0 | D | | |
| Stock Option (Right to Buy) | \$4.28 | | | | | | | | (5) | 0 | 7/12/2028 | Common Stock | 100, | 000 | | 100,000 | 0 | D | | |
| Stock Option (Right to Buy) | \$2.52 | | | | | | | | (6) | 0 | 7/01/2029 | Common Stock | 230, | 000 | | 230,000 | 0 | D | | |
| Stock Option (Right to Buy) | \$3.49 | | | | | | | | (7) | 0 | 7/02/2030 | Common Stock | 230, | 000 | | 230,000 | 0 | D | | |
| Evalanatio | | , | | | | | | , | , | | | | • | | | | _ | | • | |

- 1. One-quarter of such options shall vest on July 1, 2022 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2022.
- 2. All of such options are presently exercisable.
- 3. One-quarter of such options vested on July 6, 2018 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 6, 2018.
- 4. One-quarter of such options vested on June 22, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on June 22, 2019.
- 5. One-quarter of such options vested on July 12, 2019 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 12, 2019.
- 6. One-quarter of such options vested on July 1, 2020 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 1, 2020.
- 7. One-quarter of such options vested on July 2, 2021 and the remaining three-quarters of such options shall vest monthly over a three-year period beginning on July 2, 2021.

Remarks:

/s/ Brian G. Drazba

07/06/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.